Alpha 2.0
Login Register
» Authors » Victor Biton

Victor Biton

Explore the profile of Victor Biton including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 941
Followers 0
Related Specialties
Neurology
Pharmacology
Psychology
Top 10 Co-Authors
Michael R Sperling
William E Rosenfeld
Bassel Abou-Khalil
Pavel Klein
David Blum
Alain Vuong
Kore Liow
Gregory Krauss
Enrique Carrazana
Pamela Doty
Published In
Epilepsia
Epilepsy Behav
Epilepsy Res
Expert Rev Neurother
Clin Drug Investig
Affiliations
Soon will be listed here.
Recent Articles
1.
Perampanel as monotherapy or first adjunctive therapy in pediatric and adult patients with epilepsy: the first United States-based phase IV open-label ELEVATE study
Punia V, Klein P, Mihaylova T, Biton V, Samad O, Ngo L, et al.
J Neurol . 2024 May; 271(7):4587-4598. PMID: 38730096
ELEVATE (Study 410; NCT03288129) is the first prospective, multicenter, open-label, Phase IV study of perampanel as monotherapy or first adjunctive therapy in patients aged ≥ 4 years with focal-onset seizures...
2.
A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato® alprazolam for rapid seizure termination
French J, Biton V, Dave H, Detyniecki K, Gelfand M, Gong H, et al.
Epilepsia . 2022 Oct; 64(2):374-385. PMID: 36268811
Objective: Alprazolam administered via the Staccato® breath-actuated device is delivered into the deep lung for rapid systemic exposure and is a potential therapy for rapid epileptic seizure termination (REST). We...
3.
Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: Adjunctive cenobamate dose and seizure reduction by baseline seizure frequency
Aboumatar S, Biton V, Wechsler R, Ferrari L, Rosenfeld W
Epilepsy Res . 2022 Sep; 186:107014. PMID: 36063589
This post hoc analysis (n = 240) of a subset of study sites (10 eligible US sites) from an open-label phase 3 study assessed whether baseline seizure frequency (<3 seizures/28...
4.
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials
Ryvlin P, Dimova S, Elmoufti S, Floricel F, Laloyaux C, Nondonfaz X, et al.
Epilepsia . 2022 May; 63(8):2024-2036. PMID: 35582748
Objective: This study was undertaken to evaluate safety/tolerability and efficacy of adjunctive brivaracetam (BRV) in patients on one or two concomitant antiseizure medications (ASMs) and in patients on one specific...
5.
Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program
Sander J, Rosenfeld W, Halford J, Steinhoff B, Biton V, Toledo M
Epilepsia . 2021 Nov; 63(1):139-149. PMID: 34813673
Objective: We determined retention on open-label cenobamate therapy in the clinical development program to assess the long-term efficacy and tolerability of adjunctive cenobamate in individuals with uncontrolled focal seizures. Methods:...
6.
Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study
Sperling M, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Klein P, et al.
Epilepsia . 2021 Oct; 62(12):3005-3015. PMID: 34633084
Objective: To report long-term post hoc efficacy and safety data from 10 US study sites from an open-label Phase 3 study of adjunctive cenobamate (NCT02535091). Methods: Patients with uncontrolled focal...
7.
Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications
Rosenfeld W, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Krauss G, et al.
Epilepsia . 2021 Oct; 62(12):3016-3028. PMID: 34633074
Objective: To report post hoc results on how adjustments to baseline antiseizure medications (ASMs) in a subset of study sites (10 US sites) from a long-term, open-label phase 3 study...
8.
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
Wheless J, Miller I, Hogan R, Dlugos D, Biton V, Cascino G, et al.
Epilepsia . 2021 Aug; 62(10):2485-2495. PMID: 34418086
Objective: A Phase 3 open-label safety study (NCT02721069) evaluated long-term safety of diazepam nasal spray (Valtoco) in patients with epilepsy and frequent seizure clusters. Methods: Patients were 6-65 years old...
9.
Consistent safety and tolerability of Valtoco (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study
Miller I, Wheless J, Hogan R, Dlugos D, Biton V, Cascino G, et al.
Epilepsia Open . 2021 May; 6(3):504-512. PMID: 34033266
Objective: Need for rescue therapy differs among patients with seizure clusters. Diazepam nasal spray is approved to treat seizure clusters in patients with epilepsy ≥6 years of age. This analysis...
10.
Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study
Segal E, Tarquinio D, Miller I, Wheless J, Dlugos D, Biton V, et al.
Epilepsia . 2021 May; 62(6):1442-1450. PMID: 33942315
Objective: Diazepam nasal spray (Valtoco), indicated for acute treatment of frequent seizure activity (seizure clusters) in patients with epilepsy ≥6 years of age, is designed to be a rapid, noninvasive,...